AstraZeneca FY2025 EPS Forecast Lowered by Leerink Partnrs

AstraZeneca PLC (NASDAQ:AZN - Free Report) - Equities research analysts at Leerink Partnrs dropped their FY2025 earnings per share (EPS) estimates for shares of AstraZeneca in a research note issued on Monday, November 18th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of $5.28 for the year, down from their previous estimate of $5.31. The consensus estimate for AstraZeneca's current full-year earnings is $4.07 per share. Leerink Partnrs also issued estimates for AstraZeneca's FY2026 earnings at $6.05 EPS.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same period in the previous year, the business earned $0.87 earnings per share. The company's revenue for the quarter was up 18.0% compared to the same quarter last year.

Several other brokerages have also recently issued reports on AZN. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a "sell" rating to a "hold" rating in a report on Wednesday, November 6th. TD Cowen boosted their price target on AstraZeneca from $90.00 to $95.00 and gave the stock a "buy" rating in a report on Monday, August 12th. Finally, Erste Group Bank raised AstraZeneca from a "hold" rating to a "buy" rating in a research report on Wednesday, September 11th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $89.75.

AstraZeneca Price Performance

Shares of AstraZeneca stock traded up $0.41 during trading on Tuesday, reaching $63.80. The company's stock had a trading volume of 5,311,753 shares, compared to its average volume of 5,290,541. The business has a 50 day moving average price of $74.34 and a 200-day moving average price of $78.06. The company has a market capitalization of $197.82 billion, a P/E ratio of 30.53, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47. AstraZeneca has a 12-month low of $60.47 and a 12-month high of $87.68. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71.

Institutional Investors Weigh In On AstraZeneca

Institutional investors have recently added to or reduced their stakes in the company. McClarren Financial Advisors Inc. boosted its position in shares of AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company's stock worth $25,000 after buying an additional 247 shares during the period. GHP Investment Advisors Inc. purchased a new stake in shares of AstraZeneca in the second quarter worth about $26,000. Capital Performance Advisors LLP purchased a new stake in shares of AstraZeneca in the third quarter worth about $28,000. Pathway Financial Advisers LLC purchased a new stake in shares of AstraZeneca in the first quarter worth about $29,000. Finally, CANADA LIFE ASSURANCE Co boosted its position in shares of AstraZeneca by 40.6% in the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company's stock worth $34,000 after buying an additional 146 shares during the period. Hedge funds and other institutional investors own 20.35% of the company's stock.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.